CRPOF News and Press, Ceapro Inc From 11/29/21

– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTC...

– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 – – Q3 2021 record sales of ...

EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...

McMaster’s research team discovers new mechanism of action for PGX-YBG PGX-YBG demonstrates ability to reprogram macrophages on its own PGX-YBG may be a suitable therapeutic solution for patients with fibrotic lung disease and late stage COVID-19 patients ...

EDMONTON, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...

EDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and c...

– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second quarter sales of $4,409,000 compared to $4,666,000 for second quarter 2020 – – Cash generated from operations of $2,...

– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to conduct pre-clinical studies to characterize the in vivo bioactiv...

- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI - Phase 1 study with Ceapro’s pharmaceutical grade avenanthramide to be coordinated by MHI’s Montreal Health Innovations Coordinating Center (MHICC) and led by Dr. Jean-Clau...